SCSafia Costes

Safia Costes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Safia Costes has a total of 119 co-authors. Here are the top co-authors by number of shared publications:

  • Peter C. Butler

    Larry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA

    11 shared publications
  • Gyslaine Bertrand

    Institute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France

    9 shared publications
  • Stéphane Dalle

    Department of Dermatology, Lyon-Sud Hospital, Hospices Civils de Lyon, Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France

    9 shared publications
  • Tatyana Gurlo

    Larry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    8 shared publications
  • Magalie A. Ravier

    IGF, Université de Montpellier, CNRS, INSERM

    7 shared publications
  • Christine Longuet

    The §Samuel Lunenfeld Research Institute, Department of Medicine, Mount Sinai Hospital and the Banting and Best Diabetes Center, University of Toronto, Toronto, Ontario M5T 3L9, Canada

    5 shared publications

Latest Publications

  • Open Access

    Liens entre diabète de type 2 et maladie de Parkinson

    by Ambrine Arrar, Saad El Mallem, Magalie A. Ravier, Safia Costes

    Le diabète de type 2 et la maladie de Parkinson sont deux maladies associées au vieillissement, chacune étant considérée comme un problème majeur de santé publique dans le monde. Bien que l’une soit identifiée comme un trouble métabolique et l’autre comme une maladie neurodégénérative, des données récentes suggèrent qu’elles pourraient être épidémiologiquement liées. L’accumulation de protéines amyloïdogéniques, la résistance à l’insuline ou encore l’hyperglycémie sont autant de situations pathogéniques qui pourraient expliquer une association épidémiologique et biologique entre ces deux maladies. Cette synthèse vise à décrire les mécanismes d’altération partagés et à explorer les récentes perspectives thérapeutiques communes à ces deux maladies.

  • Open Access

    Insulin resistance induced by pesticides is overcome by pancreatic islet adaptation in a mouse model of Parkinson's disease

    by Ambrine Arrar, Nour Mesto, Roxane Descaillot, Muris Humo, Aude De Cesar, Damien Gaillard, Latifa Lakhdar, Johann Vulin, Claire Aufauvre, Raphaëlle Baumier, et al.

  • Open Access

    The nuclear receptor REV-ERBα is implicated in the alteration of β-cell autophagy and survival under diabetogenic conditions

    by Matthew R. Brown, Damien Laouteouet, Morgane Delobel, Orianne Villard, Christophe Broca, Gyslaine Bertrand, Anne Wojtusciszyn, Stéphane Dalle, Magalie A. Ravier, Aleksey V. Matveyenko, et al.

    Pancreatic β-cell failure in type 2 diabetes mellitus (T2DM) is associated with impaired regulation of autophagy which controls β-cell development, function, and survival through clearance of misfolded proteins and damaged organelles. However, the mechanisms responsible for defective autophagy in T2DM β-cells remain unknown. Since recent studies identified circadian clock transcriptional repressor REV-ERBα as a novel regulator of autophagy in cancer, in this study we set out to test whether REV-ERBα-mediated inhibition of autophagy contributes to the β-cell failure in T2DM. Our study provides evidence that common diabetogenic stressors (e.g., glucotoxicity and cytokine-mediated inflammation) augment β-cell REV-ERBα expression and impair β-cell autophagy and survival. Notably, pharmacological activation of REV-ERBα was shown to phenocopy effects of diabetogenic stressors on the β-cell through inhibition of autophagic flux, survival, and insulin secretion. In contrast, negative modulation of REV-ERBα was shown to provide partial protection from inflammation and glucotoxicity-induced β-cell failure. Finally, using bioinformatic approaches, we provide further supporting evidence for augmented REV-ERBα activity in T2DM human islets associated with impaired transcriptional regulation of autophagy and protein degradation pathways. In conclusion, our study reveals a previously unexplored causative relationship between REV-ERBα expression, inhibition of autophagy, and β-cell failure in T2DM.


  • Open Access

    Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies

    by Safia Costes, Gyslaine Bertrand, Magalie A. Ravier

    Type 2 diabetes (T2D) is characterized by chronic hyperglycemia secondary to the decline of functional beta-cells and is usually accompanied by a reduced sensitivity to insulin. Whereas altered beta-cell function plays a key role in T2D onset, a decreased beta-cell mass was also reported to contribute to the pathophysiology of this metabolic disease. The decreased beta-cell mass in T2D is, at least in part, attributed to beta-cell apoptosis that is triggered by diabetogenic situations such as amyloid deposits, lipotoxicity and glucotoxicity. In this review, we discussed the molecular mechanisms involved in pancreatic beta-cell apoptosis under such diabetes-prone situations. Finally, we considered the molecular signaling pathways recruited by glucagon-like peptide-1-based therapies to potentially protect beta-cells from death under diabetogenic situations.


  • Methods to Study Roles of β-Arrestins in the Regulation of Pancreatic β-Cell Function

    by Stéphane Dalle, Safia Costes, Gyslaine Bertrand, Magalie A. Ravier

    Novel findings reveal important functional roles for β-arrestin 1 and β-arrestin 2 in the regulation of insulin secretion, β-cell survival, and β-cell mass plasticity not only by glucose but also by G-protein-coupled receptors, such as the glucagon-like peptide-1 (GLP-1) and the pituitary adenylate cyclase-activating polypeptide (PACAP) receptors or GPR40, or tyrosine kinase receptors, such as the insulin receptor. Here, we describe experimental protocols to knock down β-arrestins by small interference RNA, to follow subcellular localization of β-arrestins in the cytosol and nucleus of the insulinoma INS-1E rat pancreatic β-cell line, and to analyze β-arrestin protein expression by Western blot using INS-1E cells and isolated mouse or human pancreatic islets. We also provide details on how to genotype β-arrestin 2 knockout (Arrb2−/−) mice and to evaluate β-arrestin-mediated roles in β-cell mass plasticity and β-cell signaling using immunocytochemistry on pancreatic sections or on primary dispersed β-cells from wild-type mice and Arrb2−/− mice.

  • Open Access

    Proteasomal degradation of the histone acetyl transferase p300 contributes to beta-cell injury in a diabetes environment

    by Lucie Ruiz, Tatyana Gurlo, Magalie A. Ravier, Anne Wojtusciszyn, Julia Mathieu, Matthew R. Brown, Christophe Broca, Gyslaine Bertrand, Peter C. Butler, Aleksey V. Matveyenko, et al.

    In type 2 diabetes, amyloid oligomers, chronic hyperglycemia, lipotoxicity, and pro-inflammatory cytokines are detrimental to beta-cells, causing apoptosis and impaired insulin secretion. The histone acetyl transferase p300, involved in remodeling of chromatin structure by epigenetic mechanisms, is a key ubiquitous activator of the transcriptional machinery. In this study, we report that loss of p300 acetyl transferase activity and expression leads to beta-cell apoptosis, and most importantly, that stress situations known to be associated with diabetes alter p300 levels and functional integrity. We found that proteasomal degradation is the mechanism subserving p300 loss in beta-cells exposed to hyperglycemia or pro-inflammatory cytokines. We also report that melatonin, a hormone produced in the pineal gland and known to play key roles in beta-cell health, preserves p300 levels altered by these toxic conditions. Collectively, these data imply an important role for p300 in the pathophysiology of diabetes.


  • ERK1 is dispensable for mouse pancreatic beta cell function but is necessary for glucose-induced full activation of MSK1 and CREB

    by Michele Leduc, Joy Richard, Safia Costes, Dany Muller, Annie Varrault, Vincent Compan, Julia Mathieu, Jean-François Tanti, Gilles Pagès, Jacques Pouyssegur, et al.

    Aims/hypothesis Insufficient insulin secretion from pancreatic beta cells, which is associated with a decrease in beta cell mass, is a characteristic of type 2 diabetes. Extracellular signal-related kinase 1 and 2 (ERK1/2) inhibition in beta cells has been reported to affect insulin secretion, gene transcription and survival, although whether ERK1 and ERK2 play distinct roles is unknown. The aim of this study was to assess the individual roles of ERK1 and ERK2 in beta cells using ERK1 (also known as Mapk3)-knockout mice (Erk1 −/− mice) and pharmacological approaches. Methods NAD(P)H, free cytosolic Ca2+ concentration and insulin secretion were determined in islets. ERK1 and ERK2 subplasmalemmal translocation and activity was monitored using total internal reflection fluorescence microscopy. ERK1/2, mitogen and stress-activated kinase1 (MSK1) and cAMP-responsive element-binding protein (CREB) activation were evaluated by western blot and/or immunocytochemistry. The islet mass was determined from pancreatic sections. Results Glucose induced rapid subplasmalemmal recruitment of ERK1 and ERK2. When both ERK1 and ERK2 were inhibited simultaneously, the rapid transient peak of the first phase of glucose-induced insulin secretion was reduced by 40% (p < 0.01), although ERK1 did not appear to be involved in this process. By contrast, ERK1 was required for glucose-induced full activation of several targets involved in beta cell survival; MSK1 and CREB were less active in Erk1 −/− mouse beta cells (p < 0.01) compared with Erk1 +/+ mouse beta cells, and their phosphorylation could only be restored when ERK1 was re-expressed and not when ERK2 was overexpressed. Finally, the islet mass of Erk1 −/− mice was slightly increased in young animals (4-month-old mice) vs Erk1 +/+ mice (section occupied by islets [mean ± SEM]: 0.74% ± 0.03% vs 0.62% ± 0.04%; p < 0.05), while older mice (10 months old) were less prone to age-associated pancreatic peri-insulitis (infiltrated islets [mean ± SEM]: 7.51% ± 1.34% vs 2.03% ± 0.51%; p < 0.001). Conclusions/interpretation ERK1 and ERK2 play specific roles in beta cells. ERK2 cannot always compensate for the lack of ERK1 but the absence of a clear-cut phenotype in Erk1 −/− mice shows that ERK1 is dispensable in normal conditions.


  • L’altération fonctionnelle de l’histone acétyl-transférase p300 contribue à un déficit des cellules bêta pancréatiques dans des situations diabétogènes

    by Lucie Ruiz, Julia Mathieu, Anne Wojtusciszyn, Magalie Ravier, Gyslaine Bertrand, Stéphane Dalle, Safia Costes

  • La β-arrestine 2 joue un rôle clé dans la signalisation du récepteur GLP-1 dans les cellules β pancréatiques

    by Gyslaine Bertrand, Michelle Leduc, Annie Varrault, Joelle Obeid, Safia Costes, Stéphane Dalle, Magalie Ravier